These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9218083)

  • 21. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds.
    Callahan MJ
    J Clin Gastroenterol; 2002 Jul; 35(1 Suppl):S58-67. PubMed ID: 12184141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine.
    Houghton LA; Atkinson W; Lockhart C; Whorwell PJ; Keevil B
    Neurogastroenterol Motil; 2007 Sep; 19(9):724-31. PubMed ID: 17539895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to intraluminal gas in irritable bowel syndrome. Motility versus perception.
    Galati JS; McKee DP; Quigley EM
    Dig Dis Sci; 1995 Jun; 40(6):1381-7. PubMed ID: 7781464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
    Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
    Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence that abnormal myoelectrical activity produces colonic motor dysfunction in the irritable bowel syndrome.
    Snape WJ; Carlson GM; Matarazzo SA; Cohen S
    Gastroenterology; 1977 Mar; 72(3):383-7. PubMed ID: 832784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.
    Kobayashi S; Ikeda K; Suzuki M; Yamada T; Miyata K
    Jpn J Pharmacol; 2001 Jul; 86(3):281-8. PubMed ID: 11488427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome].
    Wittmann T; Fehér A; Rosztóczy A; Jánosi J
    Orv Hetil; 1999 Feb; 140(9):469-73. PubMed ID: 10204402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome.
    Milo R
    Curr Med Res Opin; 1980; 6(9):577-84. PubMed ID: 6996928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiological correlates of colonic motility in patients with irritable bowel syndrome.
    Bassotti G; Crowell MD; Cheskin LJ; Chami TN; Schuster MM; Whitehead WE
    Z Gastroenterol; 1998 Sep; 36(9):811-7. PubMed ID: 9795410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
    Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome.
    Schütze K; Brandstätter G; Dragosics B; Judmaier G; Hentschel E
    Aliment Pharmacol Ther; 1997 Apr; 11(2):387-94. PubMed ID: 9146780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distal colonic motor activity in four subgroups of patients with irritable bowel syndrome.
    Cole SJ; Duncan HD; Claydon AH; Austin D; Bowling TE; Silk DB
    Dig Dis Sci; 2002 Feb; 47(2):345-55. PubMed ID: 11858232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loperamide treatment of the irritable bowel syndrome.
    Hovdenak N
    Scand J Gastroenterol Suppl; 1987; 130():81-4. PubMed ID: 3306904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral domperidone: double blind comparison with placebo in irritable bowel syndrome.
    Cann PA; Read NW; Holdsworth CD
    Gut; 1983 Dec; 24(12):1135-40. PubMed ID: 6357963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome.
    Mitch CH; Brown TJ; Bymaster FP; Calligaro DO; Dieckman D; Merrit L; Peters SC; Quimby SJ; Shannon HE; Shipley LA; Ward JS; Hansen K; Olesen PH; Sauerberg P; Sheardown MJ; Swedberg MD; Suzdak P; Greenwood B
    J Med Chem; 1997 Feb; 40(4):538-46. PubMed ID: 9046345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of postprandial colonic motility by sulpiride in patients with irritable colon.
    Lanfranchi GA; Bazzocchi G; Marzio L; Campieri M; Brignola C
    Eur J Clin Pharmacol; 1983; 24(6):769-72. PubMed ID: 6884414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged ambulant recordings of small bowel motility demonstrate abnormalities in the irritable bowel syndrome.
    Kellow JE; Gill RC; Wingate DL
    Gastroenterology; 1990 May; 98(5 Pt 1):1208-18. PubMed ID: 2323514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome.
    Awad RA; Cordova VH; Dibildox M; Santiago R; Camacho S
    Acta Gastroenterol Latinoam; 1997; 27(4):247-51. PubMed ID: 9401097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome.
    Delvaux M; Beck A; Jacob J; Bouzamondo H; Weber FT; Frexinos J
    Aliment Pharmacol Ther; 2004 Jul; 20(2):237-46. PubMed ID: 15233705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial.
    Awad R; Dibildox M; Ortiz F
    Acta Gastroenterol Latinoam; 1995; 25(3):137-44. PubMed ID: 8600700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.